^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ocrevus (ocrelizumab)

    i
    Other names: PRO 70769, R 1594, RG1594, rhuMab 2H7, PRO70769, OCR, RO4964913, PRO-70769, R1594, RO-4964913, RG 1594, RO 4964913, R-1594, RG-1594
    Associations

    News

    Trials
    Company:
    Biogen, Roche
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    Effects of Ocrevus in Relapsing Multiple Sclerosis (clinicaltrials.gov)
    P4, N=60, Active, not recruiting, Georgia State University | Trial completion date: Sep 2025 --> Dec 2025
    Trial completion date
    |
    Ocrevus (ocrelizumab)
    1d
    Assessing Peripheral Blood Biomarkers and Predictive Patterns in Multiple Sclerosis Using Cytokines and Immune Gene Expression Profiles in Ocrelizumab-Treated Patients: Tracking Tumor Necrosis Factor. (PubMed, Int J Mol Sci)
    This result implies that PBMCs' TNF mRNA expression might be potentially considered as a prognostic biomarker of ocrelizumab effectiveness in MS patients. However, further studies comprising large cohorts and additional immunological parameters are warranted.
    Journal • Gene Expression Profile
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD86 (CD86 Molecule)
    |
    Ocrevus (ocrelizumab)
    15d
    BAFF is a marker of hypogammaglobulinemia, neuroaxonal damage and inflammation in multiple sclerosis patients on ocrelizumab. (PubMed, J Neuroinflammation)
    This study provides insight into unique biomarker profile in patients on ocrelizumab. Increased BAFF was associated with lower IgG and IgA levels, biomarkers of neuroaxonal damage and inflammation in MS patients without recent acute inflammatory activity on ocrelizumab.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL20 (C-C Motif Chemokine Ligand 20) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • TNFRSF10A (TNF Receptor Superfamily Member 10a) • CDCP1 (CUB Domain Containing Protein 1) • GFAP (Glial Fibrillary Acidic Protein) • NEFL (Neurofilament Light Chain)
    |
    Ocrevus (ocrelizumab)
    17d
    Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy (clinicaltrials.gov)
    P=N/A, N=111, Not yet recruiting, Region Stockholm | Initiation date: Oct 2025 --> Feb 2026
    Trial initiation date
    |
    Rituxan (rituximab) • Ocrevus (ocrelizumab)
    18d
    Ocrelizumab Access by Socio-Economic Status (clinicaltrials.gov)
    P=N/A, N=800, Completed, Brigham and Women's Hospital | Not yet recruiting --> Completed | N=600 --> 800
    Trial completion • Enrollment change • Real-world evidence
    |
    Ocrevus (ocrelizumab)
    21d
    SurfSubQ: A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) (clinicaltrials.gov)
    P=N/A, N=842, Recruiting, Hoffmann-La Roche | N=349 --> 842 | Trial completion date: Nov 2026 --> Mar 2028 | Trial primary completion date: Nov 2026 --> Mar 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Ocrevus (ocrelizumab)
    23d
    PORTAMENTO: A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (clinicaltrials.gov)
    P2, N=182, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ocrevus (ocrelizumab)
    30d
    This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) (clinicaltrials.gov)
    P3, N=1055, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    Ocrevus (ocrelizumab)
    1m
    Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (clinicaltrials.gov)
    P3, N=175, Recruiting, Sandoz | N=518 --> 175 | Trial primary completion date: May 2027 --> Oct 2026
    Enrollment change • Trial primary completion date
    |
    Ocrevus (ocrelizumab)
    2ms
    People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Northwestern University
    New trial
    |
    Ocrevus (ocrelizumab)
    3ms
    DESIRE MS: A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov)
    P3, N=250, Not yet recruiting, University Hospital, Montpellier
    New P3 trial • Head-to-Head
    |
    Rituxan (rituximab) • Ocrevus (ocrelizumab)
    3ms
    MS-PEKOS: Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation (clinicaltrials.gov)
    P=N/A, N=134, Completed, Novartis Pharmaceuticals | Recruiting --> Completed | N=100 --> 134
    Trial completion • Enrollment change
    |
    Ocrevus (ocrelizumab)